Long-Term Tolerability of Saxagliptin as Add-On Therapy in Type 2 Diabetes (T2D): Pooled Analysis

被引：0
|
作者：
Allen, Elsie
Fleming, Doug
Berglind, Niklas
Donovan, Mark
Ohman, Peter
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1087-P
引用
收藏
页码：A298 / A299
页数：2
相关论文
共 50 条
  • [1] Long-Term Safety and Tolerability of Saxagliptin Add-On Therapy in Elderly Patients With Type 2 Diabetes
    Iqbal, Nayyar
    Allen, Elsie
    Donovan, Mark
    Ohman, Peter
    DIABETES, 2012, 61 : A299 - A299
  • [2] Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
    Iqbal, Nayyar
    Allen, Elsie
    Oehman, Peter
    CLINICAL INTERVENTIONS IN AGING, 2014, 9 : 1479 - 1487
  • [3] Saxagliptin vs Glipizide as Add-On Therapy to Metformin for Type 2 Diabetes Mellitus (T2DM): Long-Term Safety and Efficacy
    Goeke, Burkhard
    Gallwitz, Baptist
    Eriksson, Johan
    Bokelund-Singh, Sara
    Gause-Nilsson, Ingrid
    DIABETES, 2011, 60 : A305 - A305
  • [4] Efficacy and Cardiovascular (CV) Safety of Linagliptin as Add-on to Insulin in Type 2 Diabetes (T2D)-A Pooled Comprehensive Posthoc Analysis
    Zinman, Bernard
    Ahren, Bo
    Neubacher, Dietmar
    Patel, Sanjay
    Johansen, Odd Erik
    Woerle, Hans J.
    DIABETES, 2014, 63 : A274 - A274
  • [5] Long-Term Glycemic Durability of Early Add-On Pioglitazone Therapy in Patient with Type 2 Diabetes
    Lee, Jaehyuk
    Park, Se Eun
    Moon, Jae Hoon
    Kang, Eun Seok
    Ahn, Chul-Woo
    Lee, Hyun Chul
    Cha, Bong Soo
    DIABETES, 2009, 58 : A531 - A532
  • [6] Effectiveness of a screening program of type 2 diabetes (T2D) in Primary Care, and long-term incidence of T2D in Spain
    Gabriel, R.
    Vazquez-Fernandez, A.
    Marques, P.
    Novella, B.
    Moreno, S.
    Vega, S.
    Gonzalvez, L.
    Arranz, M.
    Melero, M. C.
    Montero Herrero, M. R.
    Acosta Vergara, T.
    Tuomilehto, J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [7] Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    B. Charbonnel
    G. Schernthaner
    P. Brunetti
    D. R. Matthews
    R. Urquhart
    M. H. Tan
    M. Hanefeld
    Diabetologia, 2005, 48 : 1093 - 1104
  • [8] Cardiovascular Safety of Saxagliptin as Mono- or Add-on Therapy in Patients With Type 2 Diabetes
    Frederich, Robert
    Donovan, Mark
    Berglind, Niklas
    Harris, Susan
    Chen, Roland
    Wolf, Robert
    CIRCULATION, 2009, 120 (18) : S418 - S418
  • [9] Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    Charbonnel, B
    Schernthaner, G
    Brunetti, P
    Matthews, DR
    Urquhart, R
    Tan, MH
    Hanefeld, M
    DIABETOLOGIA, 2005, 48 (06) : 1093 - 1104
  • [10] Saxagliptin (SAXA) vs Glipizide (GLIP) as Add-On Therapy to Metformin (MET) for Type 2 Diabetes (T2D): Assessment of HbA1c, Hypoglycemia, and Weight Gain
    Bouzamondo, Hakim
    Karyekar, Chetan
    Berglind, Niklas
    Allen, Elsie
    DIABETES, 2011, 60 : A305 - A305
12345